Images
A leading source of news, views and analysis on information about science and technology for global development, SciDev.Net, reports on the research performed by IDIBAPS and IRB Barcelona scientists.
In the study, co-led by Raúl Méndez, ICREA researcher at IRB Barcelona, and Cristina Fillat, head of the Gene Therapy and Cancer Group at IDIBAPS, researchers have designed a new strategy to achieve genetically modified viruses that selectively attack tumor cells without affecting healthy tissues.
“What makes our approach different is the mechanism by which the virus acquires oncoselectivity,” Cristina Fillat explains to SciDev.Net.
Link to SciDev.Net
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
